Trials / Terminated
TerminatedNCT04947579
A Study of CC-99677 in Participants With Active Ankylosing Spondylitis
A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CC-99677 in Subjects With Active Ankylosing Spondylitis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 167 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to learn about response to CC-99677 treatment by measuring signs and symptoms of Ankylosing Spondylitis (AS), objective measures of disease activity, quality of life assessments, pharmacokinetics, safety, and tolerability over a 12-week double-blind period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-99677 | Oral |
| OTHER | Placebo | Oral |
Timeline
- Start date
- 2021-08-25
- Primary completion
- 2023-02-21
- Completion
- 2023-02-21
- First posted
- 2021-07-01
- Last updated
- 2024-05-01
- Results posted
- 2024-05-01
Locations
63 sites across 8 countries: United States, China, Czechia, Germany, Poland, Romania, Spain, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04947579. Inclusion in this directory is not an endorsement.